Revenue for Q2 '10 increased to $5.7M vs. $4.1M in Q2 '09 primarily due to Pfizer collaboration for CD20 compound development; During Q2 & H1 '10, Trubion recognized $3.8M in revenue from its Abbott collaboration for TRU-015